Exelixis
EXEL
#1611
Rank
ยฃ8.03 B
Marketcap
ยฃ28.71
Share price
0.73%
Change (1 day)
61.93%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2023 (TTM): ยฃ0.22

According to Exelixis's latest financial reports the company's current EPS (TTM) is ยฃ0.22. In 2022 the company made an earnings per share (EPS) of ยฃ0.44 a decrease over its 2021 EPS that were of ยฃ0.57.

EPS history for Exelixis from 2000 to 2023

Annual EPS

Year EPS Change
2023 (TTM)ยฃ0.22-49.23%
2022ยฃ0.44-22.97%
2021ยฃ0.57100%
2020ยฃ0.29-65.09%
2019ยฃ0.82-53.91%
2018ยฃ1.78333.96%
2017ยฃ0.41-260.61%
2016-ยฃ0.25-58.75%
2015-ยฃ0.62-42.45%
2014-ยฃ1.075.3%
2013-ยฃ1.0243.48%
2012-ยฃ0.71-264.29%
2011ยฃ0.43-165.88%
2010-ยฃ0.66-32.54%
2009-ยฃ0.97-17.65%
2008-ยฃ1.1875.86%
2007-ยฃ0.67-25.64%
2006-ยฃ0.908.33%
2005-ยฃ0.83-42.86%
2004-ยฃ1.4630.34%
2003-ยฃ1.12-5.23%
2002-ยฃ1.18-0.65%
2001-ยฃ1.19-51.88%
2000-ยฃ2.47

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
ยฃ2.70 1,135.69%๐Ÿ‡ฌ๐Ÿ‡ง UK
ยฃ2.45 1,022.57%๐Ÿ‡ซ๐Ÿ‡ท France
ยฃ1.41 543.02%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ3.06 1,301.34%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ10.92 4,894.71%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ10.87 4,871.87%๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ1.44 556.55%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ7.72-3,629.83%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ0.65-396.51%๐Ÿ‡บ๐Ÿ‡ธ USA